Combined iron chelator and T-type calcium channel blocker exerts greater efficacy on cardioprotection than monotherapy in iron-overload thalassemic mice

European Journal of Pharmacology

Volumn 822, Issue , 2018, Pages 43-50

  Kumfu, Sirinart ^a,b   Khamseekaew, Juthamas ^a,b   Palee, Siripong ^a,b   Srichairatanakool, Somdet ^a   Fucharoen, Suthat ^c   Chattipakorn, Siriporn C ^a,b   Chattipakorn, Nipon ^a,b  

^a Faculty of Medicine Chiang Mai University   (Thailand)

^b CHIANG MAI UNIVERSITY   (Thailand)

^c MAHIDOL UNIVERSITY   (Thailand)

Author keywords

Apoptosis; Iron chelator; Iron overload cardiomyopathy; T type calcium channel; Thalassemia

Indexed keywords

DEFERIPRONE; EFONIDIPINE; IRON; IRON CHELATING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CALCIUM CHANNEL T TYPE; CARDIOTONIC AGENT; CHELATING AGENT; MALONALDEHYDE;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; HEART LEFT VENTRICLE FAILURE; HEART LEFT VENTRICLE FUNCTION; HEART PROTECTION; HEART RATE VARIABILITY; IRON INTAKE; IRON OVERLOAD; IRON STORAGE; MALE; MONOTHERAPY; MOUSE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; THALASSEMIA; THALASSEMIA MAJOR; TREATMENT DURATION; WILD TYPE; ANIMAL; BLOOD; C57BL MOUSE; COMPLICATION; DRUG EFFECT; DRUG INTERACTION; HEART RATE; METABOLISM; PATHOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; APOPTOSIS; CALCIUM CHANNEL BLOCKERS; CALCIUM CHANNELS, T-TYPE; CARDIOTONIC AGENTS; CHELATING AGENTS; DRUG INTERACTIONS; HEART RATE; IRON; IRON OVERLOAD; MALE; MALONDIALDEHYDE; MICE; MICE, INBRED C57BL; SIGNAL TRANSDUCTION; THALASSEMIA; VENTRICULAR DYSFUNCTION, LEFT;

EID: 85041664105     PISSN: 00142999     EISSN: 18790712     Source Type: Journal    
DOI: 10.1016/j.ejphar.2018.01.015     Document Type: Article

References (41)

1. Aessopos, A., Farmakis, D., Karagiorga, M., Voskaridou, E., Loutradi, A., Hatziliami, A., Joussef, J., Rombos, J., Loukopoulos, D., Cardiac involvement in thalassemia intermedia: a multicenter study. Blood 97 (2001), 3411–3416.
2. Aessopos, A., Kati, M., Farmakis, D., Heart disease in thalassemia intermedia: a review of the underlying pathophysiology. Haematologica 92 (2007), 658–665.
3. Bartfay, W.J., Bartfay, E., Iron-overload cardiomyopathy: evidence for a free radical–mediated mechanism of injury and dysfunction in a murine model. Biol. Res. Nurs. 2 (2000), 49–59.
4. Berdoukas, V., Farmaki, K., Carson, S., Wood, J., Coates, T., Treating thalassemia major-related iron overload: the role of deferiprone. J. Blood. Med. 3 (2012), 119–129.
5. Chen, M.P., Cabantchik, Z.I., Chan, S., Chan, G.C., Cheung, Y.F., Iron overload and apoptosis of HL-1 cardiomyocytes: effects of calcium channel blockade. PloS One, 9, 2014, e112915.
6. Crowe, S., Bartfay, W.J., Amlodipine decreases iron uptake and oxygen free radical production in the heart of chronically iron overloaded mice. Biol. Res. Nurs. 3 (2002), 189–197.
7. Eghbali, A., Kazemi, H., Taherahmadi, H., Ghandi, Y., Rafiei, M., Bagheri, B., A randomized, controlled study evaluating effects of amlodipine addition to chelators to reduce iron loading in patients with thalassemia major. Eur. J. Haematol. 99 (2017), 577–581.
8. Fernandes, J.L., Loggetto, S.R., Verissimo, M.P., Fertrin, K.Y., Baldanzi, G.R., Fioravante, L.A., Tan, D.M., Higa, T., Mashima, D.A., Piga, A., Coelho, O.R., Costa, F.F., Saad, S.T., A randomized trial of amlodipine in addition to standard chelation therapy in patients with thalassemia major. Blood 128 (2016), 1555–1561.
9. Fernandes, J.L., Sampaio, E.F., Fertrin, K., Coelho, O.R., Loggetto, S., Piga, A., Verissimo, M., Saad, S.T., Amlodipine reduces cardiac iron overload in patients with thalassemia major: a pilot trial. Am. J. Med. 126 (2013), 834–837.
10. Glickstein, H., El, R.B., Shvartsman, M., Cabantchik, Z.I., Intracellular labile iron pools as direct targets of iron chelators: a fluorescence study of chelator action in living cells. Blood 106 (2005), 3242–3250.
11. Grotto, D., Santa Maria, L.D., Boeira, S., Valentini, J., Charao, M.F., Moro, A.M., Nascimento, P.C., Pomblum, V.J., Garcia, S.C., Rapid quantification of malondialdehyde in plasma by high performance liquid chromatography-visible detection. J. Pharm. Biomed. Anal. 43 (2007), 619–624.
12. Incharoen, T., Thephinlap, C., Srichairatanakool, S., Chattipakorn, S., Winichagoon, P., Fucharoen, S., Vadolas, J., Chattipakorn, N., Heart rate variability in beta-thalassemic mice. Int. J. Cardiol. 121 (2007), 203–204.
13. Khamseekaew, J., Kumfu, S., Wongjaikam, S., Kerdphoo, S., Jaiwongkam, T., Srichairatanakool, S., Fucharoen, S., Chattipakorn, S.C., Chattipakorn, N., Effects of iron overload, an iron chelator and a T-Type calcium channel blocker on cardiac mitochondrial biogenesis and mitochondrial dynamics in thalassemic mice. Eur. J. Pharmacol., 2017.
14. Kremastinos, D.T., Farmakis, D., Iron overload cardiomyopathy in clinical practice. Circulation 124 (2011), 2253–2263.
15. Kremastinos, D.T., Farmakis, D., Aessopos, A., Hahalis, G., Hamodraka, E., Tsiapras, D., Keren, A., Beta-thalassemia cardiomyopathy: history, present considerations, and future perspectives. Circ. Heart Fail. 3 (2010), 451–458.
16. Kumfu, S., Chattipakorn, S., Chinda, K., Fucharoen, S., Chattipakorn, N., T-type calcium channel blockade improves survival and cardiovascular function in thalassemic mice. Eur. J. Haematol. 88 (2012), 535–548.
17. Kumfu, S., Chattipakorn, S., Srichairatanakool, S., Settakorn, J., Fucharoen, S., Chattipakorn, N., T-type calcium channel as a portal of iron uptake into cardiomyocytes of beta-thalassemic mice. Eur. J. Haematol. 86 (2011), 156–166.
18. Kumfu, S., Chattipakorn, S.C., Fucharoen, S., Chattipakorn, N., Dual T-type and L-type calcium channel blocker exerts beneficial effects in attenuating cardiovascular dysfunction in iron-overloaded thalassaemic mice. Exp. Physiol. 101 (2016), 521–539.
19. Lee, D.W., Lee, T.K., Cho, I.S., Park, H.E., Jin, S., Cho, H.J., Kim, S.H., Oh, S., Kim, H.S., Creation of myocardial fibrosis by transplantation of fibroblasts primed with survival factors. Am. J. Physiol. Heart Circ. Physiol. 301 (2011), H1004–H1014.
20. Lekawanvijit, S., Chattipakorn, N., Iron overload thalassemic cardiomyopathy: iron status assessment and mechanisms of mechanical and electrical disturbance due to iron toxicity. Can. J. Cardiol. 25 (2009), 213–218.
21. Lips, D.J., van der Nagel, T., Steendijk, P., Palmen, M., Janssen, B.J., van Dantzig, J.M., de Windt, L.J., Doevendans, P.A., Left ventricular pressure-volume measurements in mice: comparison of closed-chest versus open-chest approach. Basic. Res. Cardiol. 99 (2004), 351–359.
22. Liu, D.Y., Liu, Z.D., Hider, R.C., Oral iron chelators–development and application. Best. Pract. Res. Clin. Haematol. 15 (2002), 369–384.
23. Ma, Y., Podinovskaia, M., Evans, P.J., Emma, G., Schaible, U.E., Porter, J., Hider, R.C., A novel method for non-transferrin-bound iron quantification by chelatable fluorescent beads based on flow cytometry. Biochem. J. 463 (2014), 351–362.
24. Matsumura, T., Furuichi, H., Izumi, J., Suda, H., Ito, S., Takei, M., Nishi, N., Mori, T., Tanaka, Y., Kurimoto, T., [Effect of efonidipine hydrochloride, a calcium channel blocker, on the experimental cerebral ischemia/anoxia]. Nihon. Yakurigaku. Zasshi. 105 (1995), 437–446.
25. Murphy, C.J., Oudit, G.Y., Iron-overload cardiomyopathy: pathophysiology, diagnosis, and treatment. J. Card. Fail. 16 (2010), 888–900.
26. Oudit, G.Y., Sun, H., Trivieri, M.G., Koch, S.E., Dawood, F., Ackerley, C., Yazdanpanah, M., Wilson, G.J., Schwartz, A., Liu, P.P., Backx, P.H., L-type Ca2+ channels provide a major pathway for iron entry into cardiomyocytes in iron-overload cardiomyopathy. Nat. Med. 9 (2003), 1187–1194.
27. Oudit, G.Y., Trivieri, M.G., Khaper, N., Husain, T., Wilson, G.J., Liu, P., Sole, M.J., Backx, P.H., Taurine supplementation reduces oxidative stress and improves cardiovascular function in an iron-overload murine model. Circulation 109 (2004), 1877–1885.
28. Pacher, P., Nagayama, T., Mukhopadhyay, P., Batkai, S., Kass, D.A., Measurement of cardiac function using pressure-volume conductance catheter technique in mice and rats. Nat. Protoc. 3 (2008), 1422–1434.
29. Pepe, A., Meloni, A., Capra, M., Cianciulli, P., Prossomariti, L., Malaventura, C., Putti, M.C., Lippi, A., Romeo, M.A., Bisconte, M.G., Filosa, A., Caruso, V., Quarta, A., Pitrolo, L., Missere, M., Midiri, M., Rossi, G., Positano, V., Lombardi, M., Maggio, A., Deferasirox, deferiprone and desferrioxamine treatment in thalassemia major patients: cardiac iron and function comparison determined by quantitative magnetic resonance imaging. Haematologica 96 (2011), 41–47.
30. Poggiali, E., Cassinerio, E., Zanaboni, L., Cappellini, M.D., An update on iron chelation therapy. Blood. Transfus. 10 (2012), 411–422.
31. Rebouche, C.J., Wilcox, C.L., Widness, J.A., Microanalysis of non-heme iron in animal tissues. J. Biochem. Biophys. Methods 58 (2004), 239–251.
32. Rutjanaprom, W., Kanlop, N., Charoenkwan, P., Sittiwangkul, R., Srichairatanakool, S., Tantiworawit, A., Phrommintikul, A., Chattipakorn, S., Fucharoen, S., Chattipakorn, N., Heart rate variability in beta-thalassemia patients. Eur. J. Haematol. 83 (2009), 483–489.
33. Tanaka, H., Shigenobu, K., Efonidipine hydrochloride: a dual blocker of L- and T-type ca(2+) channels. Cardiovasc. Drug. Rev. 20 (2002), 81–92.
34. Tanner, M.A., Galanello, R., Dessi, C., Smith, G.C., Westwood, M.A., Agus, A., Roughton, M., Assomull, R., Nair, S.V., Walker, J.M., Pennell, D.J., A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance. Circulation 115 (2007), 1876–1884.
35. Valerio, L.G. Jr., Petersen, D.R., Characterization of hepatic iron overload following dietary administration of dicyclopentadienyl iron (Ferrocene) to mice: cellular, biochemical, and molecular aspects. Exp. Mol. Pathol. 68 (2000), 1–12.
36. Wang, Y., Wu, M., Al-Rousan, R., Liu, H., Fannin, J., Paturi, S., Arvapalli, R.K., Katta, A., Kakarla, S.K., Rice, K.M., Triest, W.E., Blough, E.R., Iron-induced cardiac damage: role of apoptosis and deferasirox intervention. J. Pharmacol. Exp. Ther. 336 (2011), 56–63.
37. Weatherall, D.J., Clegg, J.B., Inherited haemoglobin disorders: an increasing global health problem. Bull. World Health Organ. 79 (2001), 704–712.
38. Wongjaikam, S., Kumfu, S., Chattipakorn, S.C., Fucharoen, S., Chattipakorn, N., Current and future treatment strategies for iron overload cardiomyopathy. Eur. J. Pharmacol. 765 (2015), 86–93.
39. Wongjaikam, S., Kumfu, S., Khamseekaew, J., Chattipakorn, S.C., Chattipakorn, N., Restoring the impaired cardiac calcium homeostasis and cardiac function in iron overload rats by the combined deferiprone and N-acetyl cysteine. Sci. Rep., 7, 2017, 44460.
40. Wongjaikam, S., Kumfu, S., Khamseekaew, J., Sripetchwandee, J., Srichairatanakool, S., Fucharoen, S., Chattipakorn, S.C., Chattipakorn, N., Combined iron chelator and antioxidant exerted greater efficacy on cardioprotection than monotherapy in iron-overloaded rats. PloS One, 11, 2016, e0159414.
41. Yang, B., Kirby, S., Lewis, J., Detloff, P.J., Maeda, N., Smithies, O., A mouse model for beta 0-thalassemia. Proc. Natl. Acad. Sci. USA 92 (1995), 11608–11612.